[go: up one dir, main page]

MA31923B1 - Composés de 1,2,4-oxadiazole pour le traitement de maladies auto-immunes - Google Patents

Composés de 1,2,4-oxadiazole pour le traitement de maladies auto-immunes

Info

Publication number
MA31923B1
MA31923B1 MA32925A MA32925A MA31923B1 MA 31923 B1 MA31923 B1 MA 31923B1 MA 32925 A MA32925 A MA 32925A MA 32925 A MA32925 A MA 32925A MA 31923 B1 MA31923 B1 MA 31923B1
Authority
MA
Morocco
Prior art keywords
disease
treatment
formula
pharmaceutically acceptable
autoimmune diseases
Prior art date
Application number
MA32925A
Other languages
Arabic (ar)
English (en)
Inventor
Jag Paul Heer
Thomas Daniel Heightman
David Nigel Hurst
Christopher Norbert Johnson
John Skidmore
Ian David Wall
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA31923B1 publication Critical patent/MA31923B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention porte sur de nouveaux dérivés d'oxadiazoles représentés par la formule (i) ou sur un sel pharmaceutiquement acceptable de ceux-ci. Les composés représentés par la formule (i) et leurs sels pharmaceutiquement acceptables sont utiles dans le traitement d'états ou de troubles qui sont à médiation par le récepteur s1p1. En particulier, les composés représentés par la formule (i) et leurs sels pharmaceutiquement acceptables sont utiles dans le traitement de la sclérose en plaque, de maladies auto-immunes, de troubles inflammatoires chroniques, de l'asthme, de neuropathies inflammatoires, de l'arthrite, d'une transplantation, de la maladie de crohn, de la rectocolite hémorragique, d'un lupus érythémateux, du psoriasis, d'une lésion d'ischémie-reperfusion, de tumeurs solides et d'une métastase tumorale, de maladies associées à l'angiogénèse, de maladies vasculaires, d'états pathologiques douloureux, de maladies virales aiguës, d'affections intestinales inflammatoires, du diabète insulinodépendant et non insulinodépendant.
MA32925A 2007-12-21 2010-06-16 Composés de 1,2,4-oxadiazole pour le traitement de maladies auto-immunes MA31923B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0725102.8A GB0725102D0 (en) 2007-12-21 2007-12-21 Compounds
PCT/EP2008/067972 WO2009080730A1 (fr) 2007-12-21 2008-12-19 Composés de 1,2,4-oxadiazole pour le traitement de maladies auto-immunes

Publications (1)

Publication Number Publication Date
MA31923B1 true MA31923B1 (fr) 2010-12-01

Family

ID=39048652

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32925A MA31923B1 (fr) 2007-12-21 2010-06-16 Composés de 1,2,4-oxadiazole pour le traitement de maladies auto-immunes

Country Status (19)

Country Link
US (1) US20100273770A1 (fr)
EP (1) EP2220077A1 (fr)
JP (1) JP2011506572A (fr)
KR (1) KR20100108567A (fr)
CN (1) CN101945865A (fr)
AU (1) AU2008339993A1 (fr)
BR (1) BRPI0821696A2 (fr)
CA (1) CA2710055A1 (fr)
CO (1) CO6290674A2 (fr)
CR (1) CR11576A (fr)
DO (1) DOP2010000193A (fr)
EA (1) EA017669B1 (fr)
GB (1) GB0725102D0 (fr)
IL (1) IL206277A0 (fr)
MA (1) MA31923B1 (fr)
NZ (1) NZ585995A (fr)
UA (1) UA101348C2 (fr)
WO (1) WO2009080730A1 (fr)
ZA (1) ZA201003965B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
TWI431010B (zh) 2007-12-19 2014-03-21 Lilly Co Eli 礦皮質素受體拮抗劑及使用方法
GB0725101D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
GB0725105D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
PE20091339A1 (es) 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
GB0807910D0 (en) 2008-04-30 2008-06-04 Glaxo Group Ltd Compounds
GB0910674D0 (en) 2009-06-19 2009-08-05 Glaxo Group Ltd Novel compounds
WO2012019076A1 (fr) * 2010-08-06 2012-02-09 The Trustees Of Columbia University In The City Of New York Compositions et méthodes de traitement prophylactique ou thérapeutique d'une lésion d'ischémie/reperfusion cardiaque
EP2511275A1 (fr) * 2011-04-12 2012-10-17 Bioprojet Nouveaux acides pipéridiniles monocarboxyliques comme agonistes du récepteur S1P1
EP2867230B1 (fr) 2012-07-02 2020-02-12 Monsanto Technology LLC Procédé de préparation de 1,2,4-oxadiazoles 3,5-disubstitués
CN107827837B (zh) * 2017-11-21 2021-09-24 苏州朗科生物技术股份有限公司 鞘氨醇-1-磷酸受体调节剂化合物及其制备方法与应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2539438A1 (fr) * 2003-10-01 2005-04-14 Merck And Co., Inc. 1,2,4-oxadiazoles substitues 3,5-aryle, heteroaryle ou cycloalkyle servant d'agonistes du recepteur s1p
WO2005058848A1 (fr) * 2003-12-17 2005-06-30 Merck & Co., Inc. Carboxylates propanoiques 3,4-disusbstitues utilises en tant qu'agonistes du recepteur s1p (edg)
EP1804793A4 (fr) * 2004-10-22 2010-03-31 Merck Sharp & Dohme Carboxylates, sulfonates, phosphonates, phosphinates 2-(aryl)azacyclylmethyle et heterocycles utilises comme agonistes des recepteurs s1p
US20080306124A1 (en) * 2005-06-08 2008-12-11 Rainer Albert Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands
WO2007116866A1 (fr) * 2006-04-03 2007-10-18 Astellas Pharma Inc. Compose hetero
PE20091339A1 (es) * 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1

Also Published As

Publication number Publication date
EP2220077A1 (fr) 2010-08-25
BRPI0821696A2 (pt) 2015-06-16
IL206277A0 (en) 2010-12-30
EA201070783A1 (ru) 2010-12-30
US20100273770A1 (en) 2010-10-28
EA017669B1 (ru) 2013-02-28
CO6290674A2 (es) 2011-06-20
AU2008339993A1 (en) 2009-07-02
CN101945865A (zh) 2011-01-12
KR20100108567A (ko) 2010-10-07
ZA201003965B (en) 2011-03-30
UA101348C2 (ru) 2013-03-25
WO2009080730A1 (fr) 2009-07-02
CR11576A (es) 2010-09-03
GB0725102D0 (en) 2008-01-30
NZ585995A (en) 2012-12-21
CA2710055A1 (fr) 2009-07-02
JP2011506572A (ja) 2011-03-03
DOP2010000193A (es) 2010-08-15

Similar Documents

Publication Publication Date Title
MA31923B1 (fr) Composés de 1,2,4-oxadiazole pour le traitement de maladies auto-immunes
US8796247B2 (en) Indole derivative, and pharmacologically acceptable salt thereof
EP3658538A1 (fr) Composés et compositions destinés au traitement d'états pathologiques associés à une activité nlrp
CA2832377C (fr) Composes de pyridazinone et de pyridone
TW201121544A (en) Novel phenol derivative
MA31504B1 (fr) Acides benzoylamino-indan-2-carboxyliques substitues et composes apparentes
CN115697319A (zh) 三萜系化合物nrf2抑制剂的用途
MA38079A1 (fr) Composés de 2-phényl-5-hétérocyclyl-tétrahydro-2h-pyran-3-amine destinés à être utilisés dans le traitement du diabète et de ses troubles associés
US20120122931A1 (en) Indole derivative or pharmaceutically acceptable salt thereof
WO2004101529A1 (fr) Compose heterocyclique azote et son utilisation medicale
JP6033791B2 (ja) 新規ｓ１ｐ受容体調整薬
TW200925154A (en) Phenylacetic acid compound
WO2014017093A1 (fr) Composé hétérocyclique à cinq chaînons contenant de l'azote et fusionné à un cycle benzénique ou sel pharmacologiquement acceptable de celui-ci
WO2017086430A1 (fr) Composition pharmaceutique pour traiter ou prévenir la stéatohépatite non alcoolique (nash)
NZ594244A (en) Thiadiazole and oxadiazole derivatives, preparation thereof, and therapeutic use thereof
JP2020158520A (ja) ラクタム化合物誘導体およびその応用
US8222274B2 (en) Pyrrole derivative or salt thereof
WO2019208635A1 (fr) Dérivé condensé de pyrimidine
MA32473B1 (fr) Dérivés de 5-(4-méthanesulfonyl-phényl)-thiazole pour le traitement de maladies inflammatoires aiguës et chroniques
JP2024178482A (ja) 化合物、アンジオテンシンｉｉタイプ１受容体拮抗剤及び医薬組成物
EP4192448A1 (fr) Composés de thiophène destinés à être utilisés dans le traitement de la fibrose rénale
MA56324B1 (fr) Inhibiteurs de l'arginase et leurs procédés d'utilisation
JP7511060B2 (ja) ペルオキシソーム増殖剤応答性受容体活性化剤
US20220009909A1 (en) Adamts inhibitors, preparation methods and medicinal uses thereof
JP7185226B2 (ja) １，５－アンヒドロフルクトース誘導体を含むａｍｐｋ活性化剤